| The gap
The tools exist to end cervical cancer in this lifetime, yet providers and patients are still in the early stages of learning and understanding the new screening guidelines and what screening options are available and for whom. This gap has real consequences, with about a quarter of women being behind on cervical cancer screenings. Confusion about what tests to take, and when, persists, with many clinicians and patients conflating Pap smears and HPV testing. In fact, cotesting offers limited clinical value despite its common use in the United States. This misunderstanding isn’t just a technical detail, it shapes care decisions, testing frequency, and outcomes. The difference
A Pap smear examines a sample of superficial cervical cells under a microscope to detect abnormalities that could point to precancer or cancer. It still requires a speculum exam to collect that sample. HPV testing is more targeted, looking for the DNA or RNA of 14 high-risk strains of HPV, the virus responsible for nearly all cervical cancers. While the Pap identifies the cell changes, the HPV test determines the root cause before those changes even happen. Both tests have saved lives. But they are not interchangeable, and treating them as such puts the patient at risk. The fix starts with language
Electronic health records may distinguish between HPV and Pap results behind the scenes, but that nuance rarely translates to how patients experience care. A clearer opportunity is at the front end: how appointments are named and described. Instead of defaulting to a “Pap smear” or “Pap test” visit, providers could adopt standardized language like “cervical screening” as they use in the U.K., and specify in advance which test(s) may be performed, HPV testing, a Pap smear, or both. This small shift would better reflect current guidelines and help set clearer expectations for patients. Standardized follow-up guidelines and patient education are essential. Clinicians should communicate clearly: a negative HPV test is a powerful predictor that cervical cancer or precancerous changes are extremely unlikely – and that a Pap smear is not needed at that time. Modern guidelines and research underscore that, whenever available, HPV testing should be the first line of defense against cervical cancer. The Pap smear should be reserved for when there is a clinical indication to have the cervical cells evaluated. Aligning practice with evidence doesn’t just simplify care; it prevents cancer before it starts. — By MedCity Influencer Dr. Liz Swenson |
No comments